Novo Nordisk Poised to Cash in on New GLP-1 Agents to Hit 100 Billion Yen Japan Sales

Novo Nordisk looks set to rev up its diabetes business in Japan by capitalizing on its new product launches in the burgeoning GLP-1 arena, having filed oral semaglutide in July, followed by the rollout of the insulin/GLP-1 combo Xultophy (insulin...read more